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Background: Sublingual immunotherapy (SLIT) has received attention as a method for allergen immu-
notherapy. However, the mechanism of SLIT has not yet been fully investigated. Therefore, we evaluated
the effects of SLIT in a murine asthma model, sensitized by intranasal administration of house dust mite
(HDM) extracts.
Methods: Female BALB/c mice were intranasally exposed to HDM for either 3 or 5 weeks (5 consecutive
days per week). Mice were administered either low-dose (0.5 mg/day) or high-dose (5 mg/day) sub-
lingual HDM extracts for 2 weeks, followed by an additional week of intranasal exposure. Airway
hyperresponsiveness (AHR), bronchoalveolar lavage ﬂuid (BALF) cell count, cytokine levels in the BALF
and lymph node cell culture supernatants, and allergen-speciﬁc antibodies were measured. Lung his-
tology was also investigated.
Results: In mice sensitized for 5 weeks, high-dose SLIT ameliorated AHR, airway eosinophilia and goblet
cell metaplasia. In mice sensitized for 3 weeks, even low dose SLIT ameliorated AHR and airway
eosinophilia. Th2 cytokine levels in culture supernatants of submandibular lymph node cells in high-
dose SLIT mice decreased, whereas IL-10 levels increased. Total IgA in BALF increased in mice sensi-
tized for 3 or 5 weeks, and high-dose SLIT also increased allergen-speciﬁc IgG2a in mice sensitized for 5
weeks.
Conclusions: These data suggest that earlier induction of SLIT in HDM-sensitized mice provides superior
suppression of AHR and goblet cell metaplasia. The modulation of allergen speciﬁc IgG2a and local IgA
might play a role in the amelioration of AHR and airway inﬂammation.
Copyright © 2016, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Bronchial asthma is characterized by chronic allergic airway
inﬂammation, variable airway obstruction, and airwayry Medicine and Infectious
al and Dental Sciences, 1-757
.
a).
ety of Allergology.
rgology. Production and hosting by Elsehyperresponsiveness (AHR) to various stimuli. In addition, pro-
longed airway inﬂammation induces structural changes in the
airway that are difﬁcult to treat.1 To date, the initial therapy for
bronchial asthma is inhaled corticosteroids (ICS), which are
powerful enough to control the inﬂammation, and can alleviate
symptoms and restore respiratory functions. However, ICS only
treats the symptoms of inﬂammation and cannot modify the nat-
ural history of disease.2,3
Allergen immunotherapy (AIT) involves the administration of
speciﬁc allergens to patients with IgE-mediated conditions. In thisvier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
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allergic triggers, decrease the inﬂammatory response and prevent
the development of persistent disease. Furthermore, AIT is the only
curative treatment for allergic diseases, and subcutaneous immu-
notherapy (SCIT) has been demonstrated to be clinically effective in
treating asthma and rhinitis caused by allergic sensitization4;
however, SCIT requires inconvenient injections and is associated
with potentially severe systemic reactions. Thus, sublingual
immunotherapy (SLIT) has been introduced to avoid systemic re-
actions, and has recently received increased attention regarding its
potential clinical application in AIT.5
House dust mite (HDM) is the major allergen source in cases of
human asthma and perennial allergic rhinitis. The randomized
controlled trials have demonstrated that SLIT with HDM (using
SLIT-droplets or tablets) is effective in treating allergic rhinitis and
allergic bronchial asthma.6,7 Another large clinical trial of HDM
SLIT tablets in both adult and adolescent patients with bronchial
asthma is under way. Interestingly, although a large number of
animal models of HDM-induced allergic asthma have been
developed,8,9 the efﬁcacy and mechanism(s) of action for SLIT with
HDM are not fully understood. Therefore, this study aimed to
develop an animal model of allergic asthma induced by HDM, and
to investigate the effects of SLIT in mice intranasally sensitized
with HDM.Methods
Animals
Eight-week-old female BALB/c mice, free of murine-speciﬁc
pathogens, were used in this study (CLEA Japan, Tokyo, Japan).
Animals were housed under speciﬁc pathogen-free conditions and
a 12:12 h light:dark cycle. All experiments were conducted under aFig. 1. Experimental protocols. (A)Mice were intranasally exposed to puriﬁed house dust mi
for 3e7 weeks without immunization. Sublingual immunotherapy (white arrows) was admi
(B) or 3 weeks (C), as either high dose (5 mg/day) or low dose (0.5 mg/day), followed by an
saline (NS) for SLIT. At 24 h after the last HDM challenge, airway hyperresponsiveness was
further analyses. i.n., intranasal; s.l., sublingual.protocol approved by the Niigata University ethics committee for
animal experiments.
Allergen
The species of HDM used was Dermatophagoides farinae (Der f),
which was collected for preparing the dried extract (Torii Phar-
maceutical, Tokyo, Japan). To characterize the extract, the major
allergens (Der f 1; 27 kDa and Der f 2; 15 kDa) were detected by
SDS-PAGE. The BCA assay was used to determine the 4protein
concentration by absorption spectrophotometry with bovine
serum albumin as the internal standard (0.31 mgBSA/mgextract). The
major allergens' concentrations were measured using enzyme-
linked immunosorbent assays (ELISA) (Der f 1; 4.8 mg/mgextract,
Der f 2; 4.0 mg/mgextract).
HDM-induced asthma model and treatment protocol
To induce AHRwith HDM,micewere intranasally exposed to the
HDM extract (25 mg in 10 mL of saline) for 3, 5 or 7 weeks (5
consecutive days/week), without immunization (Fig. 1A). SLIT was
performed for 2 weeks (5 consecutive days/week) after intranasal
exposure, followed by an additional week of intranasal exposure
(Fig. 1B, C). Saline was sublingually administered to mice as the
control for SLIT. Twenty-four hours after the last HDM challenge,
AHR was assessed, and bronchoalveolar lavage ﬂuid (BALF), serum
and lungs were obtained for further analyses.
Sublingual administration of allergen extract
SLIT was performed by grasping the mouse by the scruff of the
neck, and carefully applying 10 mL of the allergen extract under the
tongue. The mouse was maintained in this position for 20e30 s
after administration, to prevent the animal from immediatelyte (HDM) extract (black arrows, 25 mg Der. f in 10 mL saline) for 5 consecutive days/week
nistered for 5 consecutive days/week for 2 weeks after intranasal exposure for 5 weeks
additional week of intranasal exposure. Instead of HDM extract, control mice received
assessed, and bronchoalveolar lavage ﬂuid (BALF), serum and lungs were obtained for
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low the SLIT solution, they were sacriﬁced after our preliminary
experiments, and the stomach examined for the presence of Trypan
blue. Doses of 0.5 or 5mg/mousewere used in this experiment, and
to achieve the higher dose, the allergen solution was administered
twice over a 10 min interval.
Determination of AHR
AHR was assessed by measuring the changes in respiratory
resistance in response to increasing doses of inhaled methacholine,
using the ﬂexiVent system (SCIREQ, Montreal, Quebec, Canada), as
reported previously.10 Brieﬂy, anesthetized and tracheostomized
mice were mechanically ventilated. Increasing concentrations
(0e12.5 mg/ml) of methacholine aerosol were administered
through an inline nebulizer. After delivery of aerosolized meth-
acholine, the single-compartment model was used to assess res-
piratory resistance. Data were expressed as the percent change
from baseline resistance and compliance values.
Measurement of cytokine levels in BALF and culture supernatants of
cervical lymph node cells and lung cells
Immediately after AHR was assessed, BAL was performed using
a tracheal tube, as described previously.11 Submandibular lymph
nodes were removed, and mononuclear cells (MNCs) wereFig. 2. Comparison of the development of airway hyperresponsiveness, eosinophilia and lu
HDM extract for 3e7 weeks. The detailed procedures are described in the Methods. (A) Chan
Changes in the cellular composition of BALF. (C) Levels of the indicated cytokines in BALF. (D)
24 h after the last challenge (100 magniﬁcation). Saline group (NS or NS i.n.) (a), Der. f. for
PAS-positive cells in bronchial tissue. (F) The levels of total IgE in serum. Data presented as m
group or as indicated. #P < 0.05 compared to the Der. f. exposure for 3 weeks. BM, basementprepared by usingmechanical dissociation. Lung cells were isolated
as previously described using collagenase digestion.12 MNCs and
lung cells (2.0 105 cells/well) were cultured on BD Biocoat™ T-cell
activation assay plates (BD Biosciences, San Jose, CA, USA) for 72 h,
at which time supernatants were recovered for the cytokine assays.
In some experiments, cells were cultured without serum because of
TGF-b measurement. The supernatants from cell cultures or BAL
ﬂuid were used for the measurement of cytokines and growth
factors using commercially available enzyme-linked immunosor-
bent assay (ELISA) kits, according to the manufacturers' in-
structions. ELISA kits for the detection of IL-4, IL-5 and IFN-g were
obtained from eBioscience (San Diego, CA). The IL-10, IL-13 and
TGF-b1 ELISA kits were purchased from R&D Systems.Detection of total IgE and IgA, and Der f speciﬁc IgE and IgG
antibodies
To measure total IgE and IgA levels, we used ELISA kits speciﬁc
for mouse IgE (Shibayagi, Gunma, Japan) and mouse IgA (Bethyl
Laboratories, TX, USA).
Der f speciﬁc IgE antibodies were measured using ELISA. Brieﬂy,
96-well plates were coated with 10 mg/mL a monoclonal anti-
mouse IgE antibody (23G3; Southern Biotech, AL, USA) in 0.1 M
carbonate buffer (pH 9.5) overnight at 4 C. The blocking buffer was
10% foetal bovine serum in phosphate-buffered saline, and blocking
performed for 1 h. Binding was detected using biotin-conjugatedng histology in the intranasal sensitization model. Mice were intranasally exposed to
ges in airway resistance with increasing concentrations of nebulized methacholine. (B)
Representative periodic acid-Schiff (PAS) staining (bottom), performed in lung sections
3 weeks (b), Der. f. for 5 weeks (c), Der. f. for 7 weeks (d). (E) Quantitative analysis of
ean ± standard error of the mean (SEM). *P < 0.05 or **P < 0.01 compared to the saline
membrane; Mac, macrophages; Lym, lymphocytes; Neu, neutrophils; Eos, eosinophils.
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conjugate (Roche, Basel, Switzerland). The substrate buffer was
10 mmol/L 4-methyl umbelliferyl-b-D-galactosidase/DMF.
For detection of HDM-speciﬁc IgG, horseradish peroxidase-
conjugated anti-mouse IgG antibodies (Cat No. 074-1802, KPL,
MD, USA) were used. For measurement of HDM-speciﬁc IgG sub-
class antibodies, either biotinylated IgG1 (Cat. No. 1070-08,
Southern Biotech), biotinylated IgG2a (R19-15, BD Biosciences), or
biotinylated IgG2b (R12-3, BD Biosciences) was used. Levels of Der f
speciﬁc IgE and IgG were expressed as potency (%), which was
calculated using the value of ﬂuorescence intensity. The potency
(%) ¼ (sample  negative control)/(positive control  negative
control) 100. The pooled serum of Der f-sensitized mice was used
as a positive control.Lung histology
Left lungs were ﬁxed in 10% formalin and immersed in parafﬁn.
After deparafﬁnization, samples were stained with haematoxylin
and eosin and periodic acid-Schiff (PAS) stain for histological
analysis. The histological analyses were performed as described
previously.12Fig. 3. Comparison of the effects of sublingual immunotherapy (SLIT) on the development o
sensitization model. Mice were intranasally exposed to HDM extract for 5 weeks, and rece
cedures are described in the Methods. (A) Changes in airway resistance with increasing conc
(C) Levels of the indicated cytokines in BALF. (D) Representative haematoxylin and eosin sta
24 h after the last challenge (100magniﬁcation). Control (a, d), 0.5 mg SLIT (b, e), 5 mg SLIT
as mean ± SEM from 3 independent experiments (n ¼ 12). *P < 0.05 or **P < 0.01 comp
membrane; Mac, macrophages; Lym, lymphocytes; Neu, neutrophils; Eos, eosinophils.Statistical analyses
ManneWhitney U tests were used to evaluate the differences
between all groups. The data from 3 independent experiments (4
mice/group in each experiment [n ¼ 12]) were pooled. Compari-
sons of all paired values were performed using the KruskaleWallis
test. Signiﬁcance was assumed at P values < 0.05 for all tests. The
values for all measurements were expressed as mean ± standard
error of the mean.
Results
Comparison with intranasal exposure duration on AHR, airway
inﬂammation, goblet cell metaplasia and total IgE levels in serum
Mice that were exposed to HDM for 3 weeks showed obvious
AHR to methacholine, airway eosinophilia, elevation of Th2 cyto-
kines in BALF, and goblet cell metaplasia compared with animals
that were exposed to saline. AHR and allergic airway inﬂammation
were signiﬁcantly augmented in mice exposed to HDM for 5 weeks
and these parameters were sustained in mice exposed for 7 weeks
(Fig. 2AeE). Total IgE levels in serumwere signiﬁcantly increased in
mice exposed to HDM for 5 and 7 weeks compared to mice exposed
to saline (Fig. 2F). There were no signiﬁcant changes between mice
exposed for 5 weeks and 7 weeks. From these data, we used mice
exposed for 3 or 5 weeks in this SLIT study.f airway hyperresponsiveness, eosinophilia and lung histology in the 5-week intranasal
ived SLIT at high dose (5 mg), low dose (0.5 mg) or saline (control). The detailed pro-
entrations of nebulized methacholine. (B) Changes in the cellular composition of BALF.
ining (top) and periodic acid-Schiff (PAS) staining (bottom), performed in lung sections
(c, f). (E) Quantitative analysis of PAS-positive cells in bronchial tissue. Data presented
ared to the control group. #P < 0.05 compared to 0.5 mg SLIT group. BM, basement
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in the treatment model
For the 5-week period of sensitization, mice that received high
dose SLIT (5 mg/day) showed an obvious decrease in AHR
compared with control animals. In mice that received low dose
SLIT (0.5 mg/day), AHR was not signiﬁcantly decreased compared
to control animals (Fig. 3A). In cell composition in BALF, the
number of eosinophil in both mice received high dose and low
dose SLIT was decreased compared to control animals (Fig. 3B).
The other cell types were not signiﬁcantly different between SLIT
mice and control mice (Fig. 3B). The cytokine levels in BALF were
not signiﬁcantly different between control mice and SLIT mice
(Fig. 3C). Regarding histological features, inﬂammatory cell in-
ﬁltrates, including eosinophils, around the bronchus were
ameliorated in high dose SLIT (5 mg/day), compared to control
animals. The presence of goblet cell metaplasia, a feature of airway
remodelling, was easily identiﬁed using PAS staining of the mucus
glycoproteins. Mice that received high dose SLIT, but not those that
received the low dose, showed decreased goblet cell metaplasia
(Fig. 3D, E).
For the 3-week period of sensitization, low dose SLIT (0.5 mg/
day) induced a signiﬁcant reduction of AHR. The number of eo-
sinophils in the BALF was also decreased in mice that received SLIT,
compared to mice that received saline (Fig. 4A, B). The cytokine
levels in BALF were not also signiﬁcantly different between control
mice and SLIT mice (Fig. 4C). The inﬂammatory cell inﬁltratesFig. 4. Comparison of the effects of sublingual immunotherapy (SLIT) on the development
intranasal sensitization model. Mice were intranasally exposed to HDM, and received S
increasing concentrations of nebulized methacholine. (B) Changes in the cellular composition
and eosin staining (top) and periodic acid-Schiff (PAS) staining (bottom), performed in lung s
(E) Quantitative analysis of PAS-positive cells in bronchial tissue. Data presented as mean ±
control group. BM, basement membrane; Mac, macrophages; Lym, lymphocytes; Neu, neutaround the bronchus were apparently reduced in mice that
received SLIT (Fig. 4D). PAS-positive goblet cells in the bronchus
were signiﬁcantly reduced in mice that received SLIT, compared to
mice that received saline (Fig. 4D, E).
To investigate cytokine production capacity, MNCs were har-
vested from submandibular lymph nodes and stimulated against
anti-CD3 coated plates. MNC-derived supernatant levels of IL-5 and
IL-13 signiﬁcantly decreased in high-dose SLIT mice compared to
levels in control mice. Moreover, IL-13 levels in low-dose SLIT mice
also signiﬁcantly decreased relative to levels in control mice. Levels
of the suppressive cytokine IL-10 signiﬁcantly increased in high-
dose SLIT mice compared to control mice, whereas the levels of
TGF-b1 did not differ signiﬁcantly among groups (Fig. 5). Lung cell
culture supernatants did not differ signiﬁcantly between SLIT mice
and control mice (data not shown).
Effect of SLIT on immunoglobulin in the treatment model
The IgE levels in SLITmice sensitized for both 3 and 5weekswere
not signiﬁcantly different compared to control mice, whereas IgG1
and IgG2a levels in high-dose SLIT mice signiﬁcantly increased
compared to levels in low-dose SLIT mice and control mice
(Fig. 6AeD). The IgA levels in serumwere not signiﬁcantly different
between groups (data not shown). However, BALF IgA levels in SLIT
mice sensitized for 3 weeks were signiﬁcantly increased compared
to the levels in the control mice (Fig. 6E). The BALF IgA levels after 5-
week sensitization and high dose SLIT (5 mg/day) mice were alsoof airway hyperresponsiveness (AHR), eosinophilia and lung histology in the 3-week
LIT with HDM (0.5 mg) or saline (control). (A) Changes in airway resistance with
of BALF. (C) Levels of the indicated cytokines in BALF. (D) Representative haematoxylin
ections 24 h after the last challenge (100magniﬁcation). Control (a, c) and SLIT (b, d).
SEM from 3 independent experiments (n ¼ 12). *P < 0.05 or **P < 0.01 compared to the
rophils; Eos, eosinophils.
Fig. 5. In vitro cytokine levels. Levels of interleukin (IL-4) (A), IL-5 (B), IL-13 (C), interferon g (D), IL-10 (E), and transforming growth factor b1 (F) were determined in supernatants
from submandibular lymph node mononuclear cells (MNCs) isolated from mice that received saline (control) or either high-dose (5 mg/day house dust mite extract) or low-dose
(0.5 mg/day house dust mite extract) sublingual immunotherapy. MNCs were cultured on BD Biocoat T-cell activation assay plates for 72 h. Data are presented as mean ± standard
error of the mean from 3 independent experiments carried out in triplicate. *P < 0.05 compared to the control group.
K. Shima et al. / Allergology International 66 (2017) 89e9694signiﬁcantly increased, compared to the levels in the control mice
(Fig. 6E). However, the BALF IgA levels after 5-week sensitization and
low dose SLIT (0.5 mg/day) were similar to those in the control mice.
Discussion
In the present study, we demonstrated that sublingual admin-
istration of HDM extract was able to reduce the development of
AHR, airway eosinophilia and goblet cell metaplasia in an intranasal
HDM sensitization model. SLIT is currently established as a safe and
efﬁcacious treatment for human allergic disease,6 and murine
models of SLIT have found that it is effective in reducing AHR and
airway inﬂammation.13 However, the optimal protocol for evalu-
ating the efﬁcacy of SLIT in animal models remains unclear. In this
study, we performed SLIT in two different protocols, using a model
with mice intranasally sensitized to HDM. Our results indicate that
earlier induction of SLIT was associated with suppression of AHR
and goblet cell metaplasia.
Another priority of this study was to examine the use of intra-
nasal HDM as a sensitization allergen. In most rodent model,
ovalbumin is used as the allergen, whereas HDM is a more clinically
relevant asthma allergen, and can also be used as an alternative
allergen for animal model.8 Moreover, intranasal sensitization is a
closer method in clinical situation than the intraperitoneal sensi-
tization used in rodent asthma models, as many allergens enter the
respiratory system through breathing. In clinical data, chronic
exposure of indoor allergens is thought to be one of the causes for
the development of asthma.14e16 However, compared to intraperi-
toneal sensitization, intranasal sensitization tends to show lower
AHR and airway inﬂammation, such as airway eosinophilia and Th2cytokine production. Therefore, changes in cytokine levels in BALF
in response to SLIT might be minimal at best. Moreover, intranasal
sensitization may stimulate innate lymphoid cells type 2 (ILC2) as
well as Th2 type cells involved with eosinophilic inﬂammation.
These ILC2 might be insensitivity to antigen-speciﬁc
immunotherapy.
In our study, daily intranasal HDM administration induced AHR,
airway allergic inﬂammation and airway remodelling, starting at 3
weeks, and subsequently increased at 5 weeks. In this study, early
induction of SLIT showed greater effects in AHR, airway eosino-
philia and goblet cell metaplasia. For example, goblet cell meta-
plasia in 3-week model was greatly decreased in low dose SLIT.
However, the absolute areas of PAS-positive cells were much lower
in control mice in the 3-week model compared to the control mice
in the 5-week model. In addition, the positive cells in the 3-week
model stained more faintly than those in the 5-week model. In
the 5-week model, tenfold doses of HDM were required to induce
tolerance comparable to the 3-week model. In the prophylactic
model using immunotherapy prior to sensitization, a shorter period
of SLIT was sufﬁcient to induce tolerance comparable to the ther-
apeutic model.13 Furthermore, it has been reported that the longer
period of SLIT was necessary to suppress AHR in a murine model of
birch pollen asthma.17 Therefore, a robust immune response can be
established after a relatively short period of sensitization, and it
becomes difﬁcult to modulate the response with immunotherapy.
In our current model, substantial doses of allergen (0.5 mg or 5 mg)
were required to induce SLIT. One previous study reported that
50 mg of HDM extracts (25 mg each of Dermatophagoides pter-
onyssinus and D. farinae extracts) effectively inhibited AHR and
airway inﬂammation.18 The difference between their dosage and
Fig. 6. Serum levels of Dermatophagoides farina (Der f)-speciﬁc IgE and IgG, and total IgA levels in BALF. The levels of Der f-speciﬁc IgE (A), IgG1 (B), IgG2a (C), IgG2b (D) antibodies
were measured by ELISA and were expressed as potency (%). Total IgA levels in BALF (E)were measured by commercial ELISA. Control: serum frommice that received saline in place
of sublingual immunotherapy (SLIT). 0.5 mg and 5 mg: serum from mice that received low dose SLIT (0.5 mg/day) and high dose SLIT (0.5 mg/day), respectively. 3 W and 5 W
sensitization: 3 and 5 week-intranasal sensitization mice. Data presented as mean ± SEM from three independent experiments carried out in triplicate (n ¼ 12). **P < 0.01 compared
to the control group (5 W). #P < 0.05 compared to the control group (3 W).
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SLIT or the route of allergen administration. Previous studies per-
formed SLIT for longer times than those used in the current
study.18,19 In preliminary experiments, we found that AHR to
methacholine and the cellular composition of BALF were not
signiﬁcantly different in 2-week SLIT versus 4-week SLIT (data not
shown). It is possible that longer durations of SLIT maintain the
effects of immunotherapy when lower doses of allergen are used.
The mechanisms of allergen speciﬁc immunotherapy are likely
decreased mast cell and basophil activity and degranulation, in-
duction of regulatory T cells (Tregs) that predominantly produce IL-
10, deviation of the Th2 immune response to a Th1 response, or
production of blocking antibodies (e.g., IgG4) against IgE or
IgG1.20e22 In the present study, Th2 cytokines levels from sub-
mandibular lymph node culture supernatants decreased in SLIT
mice compared to levels in control mice, and IL-10 levels signiﬁ-
cantly increased in high-dose SLIT mice. Although FoxP3-positive
regulatory T cells in lung or lymph node were not apparently
different between groups (data not shown), our data might reﬂect
the reinforcement of regulatory T cells in the draining lymph nodes.
In this study, the expansion of Tregs in lung or draining lymph node
and the signiﬁcant differences in the number of mast cells stained
by toluidine blue, or the levels of mast cell protease-1 in the BALF
were not observed in both low dose and high dose SLIT group.
However, the levels of Der f speciﬁc IgG1 and IgG2a, but not IgE,
were increased in high dose SLIT group.
Antigen-speciﬁc IgG2a is thought to indicate crucial evidence of
successful allergen speciﬁc immunotherapy, thus indicating
immunotherapeutic efﬁcacy,23,24 thus it can be considered toreﬂect a modulation of airway allergic inﬂammation. A previous
report found that IgA production at local sites was important in
suppressing airway allergic inﬂammation.18 IgA is also thought to
play a role in tolerance induction,25 and has been associated with
an improved clinical course of SLIT in grass pollen allergy pa-
tients.26 In the present study, BALF IgA levels in SLITmice sensitized
for 3 weeks were signiﬁcantly increased compared to control mice
(Fig. 5C). The BALF IgA levels after 5-week sensitization and high
dose SLIT (5 mg/day) mice were also increased, although that
change was not observed for low dose SLIT (0.5 mg/day) mice
(Fig. 5C). Although these IgA values were not allergen-speciﬁc, our
data suggest that local IgA production may play a role in sup-
pressing airway allergic inﬂammation in this model, especially after
early SLIT induction.
In SLIT models, the retention or swallowing of the sublingual
allergen is a critical factor. Given the small volume of the allergen
(10 mL), we were able to successfully apply it sublingually, and the
allergen was not detected in the stomach (using Trypan blue). If
there are some amount of unavoidable allergen inﬂux to stomach,
AHR and airway inﬂammation do not appear be affected, as our
preliminary data also showed that 5 mg of orally administered
HDM extract did not suppress AHR and airway eosinophilia (data
not shown).
In summary, we demonstrated the efﬁcacy of SLIT in HDM
sensitized mice, using a model of established airway allergic
inﬂammation with repeated intranasal allergen administration.
Our data suggests that early induction of SLIT provides more
effective suppression of AHR and goblet cell metaplasia in the
therapeutic model. Moreover, the modulation of allergen-speciﬁc
K. Shima et al. / Allergology International 66 (2017) 89e9696IgG and local IgA production may play a role in the amelioration of
AHR and airway allergic inﬂammation. However, the precise
mechanism(s) of action remain unknown, and should be addressed
in the future.
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